N-acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development

Cancer Lett. 1999 Feb 8;136(1):83-7. doi: 10.1016/s0304-3835(98)00311-5.


The potential involvement of N-acetyltransferase 1 (NAT1) genetic polymorphisms in prostate cancer (PCa) patients was analyzed in 101 patients with PCa and 97 controls with no incidental malignancy. Identification of NAT1*10, the variant allele associated with the rapid acetylator phenotype was by allele-specific polymerase chain reaction (PCR). When the NAT1*10 heterozygote and other genotypes without NAT1*10 allele were considered as low risk genotypes, NAT1*10/NAT1*10 had a significantly higher risk of PCa (OR = 2.4, 95% CI; 1.0-5.6). If our preliminary results can be confirmed in a larger population, it may be a useful marker for PCa risk.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Arylamine N-Acetyltransferase / genetics*
  • Biomarkers, Tumor / genetics*
  • Case-Control Studies
  • Genotype
  • Heterozygote
  • Humans
  • Isoenzymes / genetics*
  • Male
  • Polymerase Chain Reaction
  • Polymorphism, Genetic*
  • Prostatic Neoplasms / enzymology*
  • Prostatic Neoplasms / genetics*
  • Risk
  • Risk Factors


  • Biomarkers, Tumor
  • Isoenzymes
  • Arylamine N-Acetyltransferase
  • N-acetyltransferase 1